Serum MicroRNAs as Diagnostic Biomarkers of Colorectal Cancer
1 other identifier
observational
80
0 countries
N/A
Brief Summary
evaluation the diagnostic value of certain MicroRNAs as biomarkers of Colorectal cancer by comparing its expression levels in Colorectal cancer patients and normal individuals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2025
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 12, 2024
CompletedFirst Posted
Study publicly available on registry
December 17, 2024
CompletedStudy Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
December 27, 2024
December 1, 2024
2 years
December 12, 2024
December 20, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
evaluation the diagnostic value of miRNAs as biomarkers of CRC by comparing its expression levels in CRC patients and normal individuals
use the results of measurement of certain serum miRNAs in persons with CRC and non-CRC individuals.
baseline
Secondary Outcomes (2)
assessment the correlation between miRNAs expression levels and clinicopathological features such as tumor stage, grade, and metastasis
baseline
evaluation the sensitivity, specificity, and diagnostic accuracy of miRNAs as standalone biomarkers
baseline
Study Arms (2)
cases
Persons has Colorectal cancer
Control
Persons do not have Colorectal cancer
Interventions
miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer
Eligibility Criteria
Patients attending assiut university hospital
You may qualify if:
- Adults (age 18-75) diagnosed with primary CRC (histopathologically confirmed).
- CRC patients who have not received prior treatment (i.e., chemotherapy or radiation).
- Age-matched healthy controls without colorectal disease
You may not qualify if:
- Patients with secondary tumors or metastasis originating from non-colorectal sources.
- Patients with prior history of CRC.
- Patients who refuse to contribute in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bishoy Shehatalead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant lecturer
Study Record Dates
First Submitted
December 12, 2024
First Posted
December 17, 2024
Study Start
March 1, 2025
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
May 1, 2027
Last Updated
December 27, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share